JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer

Overexpression of c-Myc is commonly seen in human ovarian cancers, and this could be a potentially novel therapeutic target for this disease. JQ1, a selective small-molecule BET (Bromodomain and extraterminal domain family) bromodomain (BRDs) inhibitor, has been found to suppress tumour progression in several cancer cell types.

Source: European Journal of Cancer - January 12, 2020 Category: Cancer & Oncology Authors: Tina Bagratuni, Nefeli Mavrianou, Nikolaos G. Gavalas, Kimon Tzannis, Calliope Arapinis, Michael Liontos, Maria I. Christodoulou, Nikolaos Thomakos, Dimitrios Haidopoulos, Alexandros Rodolakis, Efstathios Kastritis, Andreas Scorilas, Meletios A. Dimopoulo Tags: Original Research Source Type: research